Kynetyka Technologies Pty Ltd
ABN 88 614 880 956
65 Hardys Road Underdale SA 5032
www.kynetyka.com.au

MEDIA RELEASE

Kynetyka secures TTRA funding to advance DVTect® deep vein thrombosis test.

1 October 2026; Adelaide Australia: Adelaide-based medical device company Kynetyka Technologies Pty Ltd ("Kynetyka") announces that it has secured $795,000 in funding through AUScelerate's Targeted Translation Research Accelerator program for Diabetes and Cardiovascular Disease, supported by the Medical Research Future Fund (MRFF). The non-dilutive funding and commercialisation support will accelerate a $1.2 million project to advance DVTect® - the easy early test for Deep Vein Thrombosis (DVT).

DVTect® is an innovative point-of-care, sensor-plus-software medical device designed for bedside use by nurses and healthcare professionals. By enabling rapid, accurate DVT testing, DVTect® speeds up clinical decision-making and treatment to help prevent life-threatening complications.

The TTRA-funded project will focus on developing and optimizing the DVTect® software, underpinned by a Quality Management System, guided by user requirement specifications and consumer involvement, and validated through clinical testing.

Kynetyka CEO and Project Leader, Craig Newton, noted the strategic value of the TTRA program:
"This TTRA financial support is transformative for Kynetyka and for the future of DVT management. The rigorous three-stage selection process and the endorsement from the TTRA Investment Panel - comprising clinical, industry, and lived-experience expert - validates the clear clinical need for DVTect® across hospitals, communities, and rural and remote regions globally. We also want to thank the AUScelerate team for their support, diligence, and insightful feedback throughout the application process."

Kynetyka COO and Project Manager, Peter Bradley, outlined the next steps for the project to take it to clinical trials:
"As we initiate this project, Kynetyka is convening a multidisciplinary team of software designers and engineers, clinicians and nurses, regulatory and quality specialists, regional healthcare advisors, and people with lived experience. Together, we will optimise and test DVTect® in preparation for our definitive pivotal clinical trial in late 2027".

For further information, contact Kynetyka:

Craig Newton, CEO and Managing Director
cnewton@kyetyka.com.au
Phone: +61 (0) 434 674 256

Kynetyka Technologies Pty Ltd
Kynetyka Technologies Pty Ltd (Kynetyka) is an Australian medical device company, headquartered in Adelaide. The company is developing and commercialising DVTect®, a unique, patented, point-of-care software and device to detect Deep Vein Thrombosis.
Kynetyka is led by a team of respected clinicians and professionals. The executive team has collectively over 120 years' global experience in medical, pharmaceutical, and technology development sectors.

Deep Vein Thrombosis (DVT)
DVT is a blood clot in a vein, often in the leg. The clot can dislodge, travel to the lungs and lead to life-threatening pulmonary embolism and sometimes death. The USA Centre for Disease Control estimates there are up to 900,000 affected and 100,000 deaths in the USA per annum. There are approximately 8,000 deaths in Australia every year.
Currently, DVT testing is performed using doppler ultrasound, but 75% to 80% of ultrasounds for suspected DVT do not find a DVT in the patient. Due to delays for results from both ultrasound and blood tests, patient may receive anticoagulants out of caution. These drugs may result in bleeding and complications.

DVTect® technology
When a patient has a deep vein thrombosis (DVT) in the leg, there is a demonstrable change in the calf muscles. The DVTect® test starts with the DVTect sensor attached to a leg, which is lightly tapped to cause movement in the muscle. The resulting 3D waveform data is recorded and transmitted to the DVTect® software, where it is analysed for the presence of DVT with test results presented on a smart device, computer, or bedside monitoring equipment. DVTect® is protected by granted patents in North America, Europe and Australasia.

DVTect® is faster and easier to use than all ultrasound devices and is designed to be used at the hospital bedside and in the community. DVTect® is designed to reduce needless ultrasounds, deaths from pulmonary embolisms, and overuse of anticoagulants, and help address workforce shortages of sonographers.